This HTML5 document contains 125 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/bindingdb/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/mixture/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/pubchem-substance/
n24http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/iuphar/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/national-drug-code-directory/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n32http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00871/identifier/wikipedia/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00871
rdf:type
n3:Drug
n3:description
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]
n3:dosage
n15:271B5380-363D-11E5-9242-09173F13E4C5 n15:271B5381-363D-11E5-9242-09173F13E4C5 n15:271B5382-363D-11E5-9242-09173F13E4C5 n15:271B5383-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14610225 # Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1358833 # Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2062329
n3:group
approved
n3:halfLife
5.5-5.9 hours
n3:indication
For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
n3:manufacturer
n4:271B5377-363D-11E5-9242-09173F13E4C5 n4:271B5375-363D-11E5-9242-09173F13E4C5 n4:271B5376-363D-11E5-9242-09173F13E4C5 n4:271B536F-363D-11E5-9242-09173F13E4C5 n4:271B5370-363D-11E5-9242-09173F13E4C5 n4:271B536E-363D-11E5-9242-09173F13E4C5 n4:271B5373-363D-11E5-9242-09173F13E4C5 n4:271B5374-363D-11E5-9242-09173F13E4C5 n4:271B5371-363D-11E5-9242-09173F13E4C5 n4:271B5372-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00871 n24:DB00871
dcterms:title
Terbutaline
adms:identifier
n8:Terbutaline n19:0143-9746-10 n21:PA451616 n22:560 n23:C07129 n25:5403 n26:46506887 n28:25770 n29:560 n30:5210 n31:DB00871
n3:mechanismOfAction
The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
n3:packager
n4:271B535C-363D-11E5-9242-09173F13E4C5 n4:271B535D-363D-11E5-9242-09173F13E4C5 n4:271B5356-363D-11E5-9242-09173F13E4C5 n4:271B535B-363D-11E5-9242-09173F13E4C5 n4:271B536B-363D-11E5-9242-09173F13E4C5 n4:271B536C-363D-11E5-9242-09173F13E4C5 n4:271B5369-363D-11E5-9242-09173F13E4C5 n4:271B536A-363D-11E5-9242-09173F13E4C5 n4:271B5367-363D-11E5-9242-09173F13E4C5 n4:271B5368-363D-11E5-9242-09173F13E4C5 n4:271B5365-363D-11E5-9242-09173F13E4C5 n4:271B5366-363D-11E5-9242-09173F13E4C5 n4:271B535A-363D-11E5-9242-09173F13E4C5 n4:271B5358-363D-11E5-9242-09173F13E4C5 n4:271B5359-363D-11E5-9242-09173F13E4C5 n4:271B5357-363D-11E5-9242-09173F13E4C5 n4:271B5361-363D-11E5-9242-09173F13E4C5 n4:271B5362-363D-11E5-9242-09173F13E4C5 n4:271B5360-363D-11E5-9242-09173F13E4C5 n4:271B536D-363D-11E5-9242-09173F13E4C5 n4:271B5354-363D-11E5-9242-09173F13E4C5 n4:271B5355-363D-11E5-9242-09173F13E4C5 n4:271B5353-363D-11E5-9242-09173F13E4C5 n4:271B5363-363D-11E5-9242-09173F13E4C5 n4:271B5364-363D-11E5-9242-09173F13E4C5 n4:271B535E-363D-11E5-9242-09173F13E4C5 n4:271B535F-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination
n3:synonym
Terbutalinsulfat Terbutalini sulfas Terbutalinum Terbutalina Terbutalin Terbutaline (sulfate de)
n3:toxicity
Terbutaline Sulfate: Oral LD<sub>50</sub>(rat) = 8.7 g/kg; Oral LD<sub>50</sub>(mouse) = 205 mg/kg; Oral LD<sub>50</sub>(dog) = 1.5 g/kg; IP LD<sub>50</sub>(rat)= 220 mg/kg ; IP LD<sub>50</sub>(mouse) = 130 mg/kg; Oral LD<sub>50</sub>(rabbit) = >8 g/kg; IV LD<sub>50</sub>(mouse) = 36 mg/kg; IV LD<sub>50</sub>(dog) = 116 mg/kg; IV LD<sub>50</sub>(rabbit) = 110 mg/kg
n5:hasAHFSCode
n16:12-12-08-12
n3:mixture
n20:271B534F-363D-11E5-9242-09173F13E4C5 n20:271B5350-363D-11E5-9242-09173F13E4C5 n20:271B5351-363D-11E5-9242-09173F13E4C5 n20:271B5352-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.
n12:hasConcept
n13:M0021177
foaf:page
n10:terbutaline.htm n32:terbutaline.html
n3:IUPAC-Name
n11:271B5388-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B538E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B538D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B538A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B538B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B538C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B5386-363D-11E5-9242-09173F13E4C5 n11:271B539E-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B5384-363D-11E5-9242-09173F13E4C5 n11:271B5387-363D-11E5-9242-09173F13E4C5 n11:271B53A0-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B5385-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:R03AC03 n6:R03CC03
n3:H-Bond-Acceptor-Count
n11:271B5394-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B5395-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B538F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B5390-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B5392-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B5391-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B5393-363D-11E5-9242-09173F13E4C5
n3:absorption
Approximately 30-50% if administered orally and well absorbed subcutaneously.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n11:271B53A1-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
23031-25-6
n3:category
n3:clearance
* 311 +/- 112 mL/min
n3:containedIn
n27:271B537C-363D-11E5-9242-09173F13E4C5 n27:271B537D-363D-11E5-9242-09173F13E4C5 n27:271B537A-363D-11E5-9242-09173F13E4C5 n27:271B537B-363D-11E5-9242-09173F13E4C5 n27:271B5378-363D-11E5-9242-09173F13E4C5 n27:271B5379-363D-11E5-9242-09173F13E4C5 n27:271B537E-363D-11E5-9242-09173F13E4C5 n27:271B537F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B539A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B539C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B539D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B539F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B5399-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B5398-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B539B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B5389-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n11:271B5396-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B5397-363D-11E5-9242-09173F13E4C5